Electromed, Inc., Appoints Christopher Holland Chief Commercial Officer

Key Facts

• “I am very excited to be joining the Electromed team” > > Tweet this Mr. Holland, an accomplished sales and marketing veteran, brings 30 years of experience in driving commercial growth in the Medical Technology market to Electromed.

• Prior to joining Electromed, Holland was the Vice President of Commercialization at Prosomnus Sleep Technologies, Inc., a Medical Device manufacturer of a mandibular advancement device for sleep apnea where he led new product introduction and revenue-growth initiatives across the enterprise.
• Prior to his time at Prosomnus, Holland spent over a decade as the Chief Commercial Officer and Executive Vice President of Sales and Global Business Development at Nonin Medical, Inc., where his accomplishments included delivering record global sales by successfully initiating and leading a corporate commercial turnaround.
• Examples of risks and uncertainties for the Company include, but are not limited to, the duration, extent and severity of the COVID-19 pandemic, including its effects on our business, operations and employees as well as its impact on our customers and distribution channels and on economies and markets more generally; the competitive nature of our market; changes to Medicare, Medicaid, or private insurance reimbursement policies; changes to state and federal health care laws; changes affecting the medical device industry; our ability to develop new sales channels for our products such as the homecare distributor channel; our need to maintain regulatory compliance and to gain future regulatory approvals and clearances; new drug or pharmaceutical discoveries; general economic and business conditions; our ability to renew our line of credit or obtain additional credit as necessary; our ability to protect and expand our intellectual property portfolio; the risks associated with expansion into international markets, as well as other factors we may describe from time to time in the Company’s reports filed with the Securities and Exchange Commission (including the Company’s most recent Annual Report on Form 10-K, as amended from time to time, and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K).

Click To Read Full Article